Directed Alternative Splicing in Nijmegen Breakage Syndrome: Proof of Principle Concerning Its Therapeutical Application
Standard
Directed Alternative Splicing in Nijmegen Breakage Syndrome: Proof of Principle Concerning Its Therapeutical Application. / Salewsky, Bastian; Hildebrand, Gabriele; Rothe, Susanne; Parplys, Ann Christin; Radszewski, Janina; Kieslich, Moritz; Wessendorf, Petra; Krenzlin, Harald; Borgmann, Kerstin; Nussenzweig, André; Sperling, Karl; Digweed, Martin.
in: MOL THER, Jahrgang 24, Nr. 1, 12.08.2015, S. 117-124.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Directed Alternative Splicing in Nijmegen Breakage Syndrome: Proof of Principle Concerning Its Therapeutical Application
AU - Salewsky, Bastian
AU - Hildebrand, Gabriele
AU - Rothe, Susanne
AU - Parplys, Ann Christin
AU - Radszewski, Janina
AU - Kieslich, Moritz
AU - Wessendorf, Petra
AU - Krenzlin, Harald
AU - Borgmann, Kerstin
AU - Nussenzweig, André
AU - Sperling, Karl
AU - Digweed, Martin
PY - 2015/8/12
Y1 - 2015/8/12
N2 - Over 90% of patients with Nijmegen breakage syndrome (NBS), a hereditary cancer disorder, are homoallelic for a 5 bp deletion in the NBN gene involved in the cellular response to DNA damage. This hypomorphic mutation leads to a carboxy-terminal protein fragment, p70-nibrin, with some residual function. Average age at malignancy, typically lymphoma, is 9.7 years. NBS patients are hypersensitive to chemotherapeutic and radiotherapeutic treatments, thus prevention of cancer development is of particular importance. Expression of an internally deleted NBN protein, p80-nibrin, has been previously shown to be associated with a milder cellular phenotype and absence of cancer in a 62-year-old NBS patient. Here we show that cells from this patient, unlike other NBS patients, have DNA replication and origin firing rates comparable to control cells. We used here antisense oligonucleotides to enforce alternative splicing in NBS patient cells and efficiently generate the same internally deleted p80-nibrin protein. Injecting the same antisense sequences as morpholino oligomers (VivoMorpholinos) into the tail vein of a humanized NBS murine mouse model also led to efficient alternative splicing in vivo. Thus, proof of principle for the use of antisense oligonucleotides as a potential cancer prophylaxis has been demonstrated.Molecular Therapy (2015); doi:10.1038/mt.2015.144.
AB - Over 90% of patients with Nijmegen breakage syndrome (NBS), a hereditary cancer disorder, are homoallelic for a 5 bp deletion in the NBN gene involved in the cellular response to DNA damage. This hypomorphic mutation leads to a carboxy-terminal protein fragment, p70-nibrin, with some residual function. Average age at malignancy, typically lymphoma, is 9.7 years. NBS patients are hypersensitive to chemotherapeutic and radiotherapeutic treatments, thus prevention of cancer development is of particular importance. Expression of an internally deleted NBN protein, p80-nibrin, has been previously shown to be associated with a milder cellular phenotype and absence of cancer in a 62-year-old NBS patient. Here we show that cells from this patient, unlike other NBS patients, have DNA replication and origin firing rates comparable to control cells. We used here antisense oligonucleotides to enforce alternative splicing in NBS patient cells and efficiently generate the same internally deleted p80-nibrin protein. Injecting the same antisense sequences as morpholino oligomers (VivoMorpholinos) into the tail vein of a humanized NBS murine mouse model also led to efficient alternative splicing in vivo. Thus, proof of principle for the use of antisense oligonucleotides as a potential cancer prophylaxis has been demonstrated.Molecular Therapy (2015); doi:10.1038/mt.2015.144.
U2 - 10.1038/mt.2015.144
DO - 10.1038/mt.2015.144
M3 - SCORING: Journal article
C2 - 26265251
VL - 24
SP - 117
EP - 124
JO - MOL THER
JF - MOL THER
SN - 1525-0016
IS - 1
ER -